BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 27, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

GFT505: Phase II started

Genfit began the 12-week, double-blind, placebo-controlled, European Phase II GFT505-210-5 trial to evaluate 80 mg/day oral GFT505 in 120 newly-diagnosed Type...

Read the full 85 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >